oalib

OALib Journal期刊

ISSN: 2333-9721

费用：99美元

投稿

时间不限

( 2026 )

( 2025 )

( 2024 )

( 2023 )

自定义范围…

匹配条件： “Autologous Blood Therapy” ，找到相关结果约1000条。
列表显示的所有文章，均可免费获取
第1页/共1000条
每页显示 条
Autologous cord blood harvesting in North Eastern Italy: ethical questions and emerging hopes for curing diabetes and celiac disease
Parco S, Vascotto F
International Journal of General Medicine , 2012, DOI: http://dx.doi.org/10.2147/IJGM.S31977
Abstract: utologous cord blood harvesting in North Eastern Italy: ethical questions and emerging hopes for curing diabetes and celiac disease Original Research (1691) Total Article Views Authors: Parco S, Vascotto F Video abstract presented by Sergio Parco Views: 19 Published Date June 2012 Volume 2012:5 Pages 511 - 516 DOI: http://dx.doi.org/10.2147/IJGM.S31977 Received: 20 March 2012 Accepted: 20 April 2012 Published: 15 June 2012 Sergio Parco, Fulvia Vascotto Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy Background: The Friuli Venezia Giulia (FVG), a region of North Eastern Italy, has passed legislation (Decree No 2324/2010) to regulate the banking of umbilical cord blood samples for personal, autologous, or family-directed use, and to implement the Agreement of the State-Regions Permanent Conference (Decree No 62/CSR/2010). This paper aims to identify the formalities and the reasons why families collect and bank their cord blood in foreign banks for both personal and private use. Methods: To this end, at the Institute for Maternal and Child Health of Trieste (the regional capital city of the FVG), Italy, which assists about 1800 pregnant women a year, 129 questionnaires, drafted from January 2010 to December 2011 and concerning the granting of authorization to export samples, were examined. Results: The collected data showed that 75% of involved families had resorted to anonymous public collection, which is available to anyone with therapeutic needs, and provided compatibility and hematologic protocols recognized by the scientific and international community (main indications: leukemia, hemoglobinopaties, and inherited hematologic and immunologic disorders). Conversely, 25.0% requested private storage at a foreign bank for personal or family-dedicated use. The principal motivation by disease was for treatment for diabetes (22.4%) and celiac disease (19.7%) (a multiorgan disease for which the FVG region has provided safeguards by approving a specific law granting support to families; Decree No 561/2007). For these two types of disease we found that information was received from the internet and not from general medical physicians, with a significant difference found using the χ2 test (P < 0.01). Conclusion: The indication of treating these diseases with cord blood stem cell transplantation appears to be well grounded and encouraging, and has recently been corroborated by the international literature; however, the economic and social motivations promoting cord blood storage, for a fee, in the event of diseases that are still under study, require accurate information through general medical physicians on the actual possibilities of treatment.
Hemoterapia en el trasplante de médula ósea: Experiencia en el instituto de hematología e inmunología
Alfonso Valdés,María E; Bencomo Hernández,Antonio; Dorticós Balea,Elvira; Hernández Díaz,Patricia; Alfonso Valdés,Yalile; González Otero,Alejandro;
Revista Cubana de Hematolog？-a, Inmunolog？-a y Hemoterapia , 1999,
Abstract: the hemotherapy applied to 19 patients with malignant hematological diseases that underwent autologous bone marrow transplantation (n=10) and allogeneic bone marrow transplantation (n=9) is described. the average consumption of erythrocytes concentrates and of platelets concentrates was 6.1 and 57.3 respectively. the use of both component was higher among those patients that received an allogeneic bone marrow. the patients who were treated with cyclosporine required a higher number of erythrocyte and platelet concentrates than those who did not receive this immunosupressor. as abo donor-recepient incompatibility was observed in 3 cases, some measures were taken to prevent posttransplantation hemolysis. in the case with mejor incompatibility erythrocytes were eliminated from the bone marrow, the recipient underwent plasmaphaeresises and received a transfusion of incompatible abo erythrocytes. in the case with minor incompatibility, plasma was removed from the bone marrow. in 1 case with mixed incompatibility the measures taken in the previous cases were combined. there was no posttransplantation hemolysis in any of the cases
基于“治风先治血”理论辨治慢性难治性荨麻疹
Differentiation and Treatment of Chronic Refractory Urticaria Based on the Theory of “Treating Blood before Treating Wind”  [PDF]
杨纯清, 吴健文
Traditional Chinese Medicine (TCM) , 2026, DOI: 10.12677/tcm.2026.151035
Abstract: 慢性难治性荨麻疹是一种病程超过6周、反复发作且常规治疗(如抗组胺药)效果不佳的皮肤疾病，临床表现为风团、瘙痒等。该文章基于“治风先治血”理论，着眼于风血辨证，运用刺络拔罐联合自血疗法治疗慢性难治性荨麻疹，取得较好疗效。并附验案1则，以资验证，可为现代医学治疗慢性难治性荨麻疹提供新的思路和解决方案。
Chronic refractory urticaria is a skin disease with a course of more than 6 weeks, recurrent attacks and poor response to conventional treatment (such as antihistamines). Its clinical manifestations include wheals, pruritus, etc. Based on the theory of “treating blood before treating wind”, this article focuses on the syndrome differentiation of wind and blood, and uses the combination of acupressure cupping and autohemotherapy to treat chronic refractory urticaria, achieving good therapeutic effects. Attached is one case for verification, which can provide new ideas and solutions for the modern medical treatment of chronic refractory urticaria.
High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma
Baldissera, R.C.;Aranha, J.F.P.;Oliveira, G.B.;Vigorito, A.C.;Eid, K.A.B.;Miranda, E.C.M.;De Souza, C.A.;
Brazilian Journal of Medical and Biological Research , 2002, DOI: 10.1590/S0100-879X2002000100007
Abstract: trials have demonstrated that high-dose escalation followed by autologous transplantation can promote better long-term survival as salvage treatment in malignant lymphomas. the aim of the present nonrandomized clinical trial was to demonstrate the role of high-dose cyclophosphamide (hdcy) in reducing tumor burden and also to determine the effectiveness of hdcy followed by etoposide (vp-16) and methotrexate (mtx) in hodgkin's disease plus high-dose therapy with peripheral blood progenitor cell (pbpc) transplantation as salvage treatment. from 1998 to 2000, 33 patients with a median age of 33 years (13-65) affected by aggressive non-hodgkin's lymphoma (nhl) (60.6%) or persistent or relapsed hodgkin's disease (39.4%) were enrolled and treated using high dose escalation (hdcy + hdvp-16 plus hdmtx in hodgkin's disease) followed by autologous pbpc transplantation. on an "intention to treat" basis, 33 patients with malignant lymphomas were evaluated. the overall median follow-up was 400 days (40-1233). thirty-one patients underwent autografting and received a median of 6.19 x 106/kg (1.07-29.3) cd34+ cells. patients who were chemosensitive to hdcy (n = 22) and patients who were chemoresistant (n = 11) presented an overall survival of 96 and 15%, respectively (p<0.0001). overall survival was 92% for chemosensitive patients and 0% for patients who were still chemoresistant before transplantation (p<0.0001). toxicity-related mortality was 12% (four patients), related to hdcy in two cases and to transplant in the other two. hdcy + hdvp-16 plus hdmtx in only hodgkin's disease followed by autologous pbpc proved to be effective and safe as salvage treatment for chemosensitive patients affected by aggressive nhl and hodgkin's disease, with acceptable mortality rates related to sequential treatment.
Autologous serum in treatment of dry eye
Stankovi？-Babi？ Gordana,Ceki？ Sonja
Medicinski Pregled , 2012, DOI: 10.2298/mpns1212511s
Abstract: Introduction. The treatment of dry eye by autologous serum is a simple and inexpensive treatment option. It is particularly effective in severe forms of dry eye as well as for chemical eye injuries, and it is justified by the presence of essential tear components which are not found in preparations of artificial tears. The aim of this study was to analyze the effects of autologous serum therapy in the patients with dry eye. Material and Methods. We monitored the effect of one-month treatment of dry eye by autologous serum (used with artificial tear preparations) in 50 rheumatology patients (23 men and 27 women) aged 26-65 years at the Department of Ophthalmology, Clinical Center Nis. We analyzed ocular discomfort and the values of objective parameters for the evaluation of tear film at baseline and one month later (Schirmer I, Tears Break Up Time and Rose Bengal). Results. A statistically significant reduction of subjective complaints was found in the patients after the treatment by autologous serum (p<0.05), along with a minimal improvement of objective tests for checking the tear film quality. Discussion and Conclusion. The use of autologous serum in dry eye therapy should provide benefit to the patients, relieve symptoms and improve objective parameters for the evaluation of dry eye. Both doctors and patients should be adequately informed, and proper screening of potential users of this method should be done. Not only additional tests of therapeutic effect of autologous serum (as well as of umbilical cord serum or autologous plasma) are needed but also parallel clinical and histopathological examination and analysis of the effects of this type of treatment of dry eye.
High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma
Baldissera R.C.,Aranha J.F.P.,Oliveira G.B.,Vigorito A.C.
Brazilian Journal of Medical and Biological Research , 2002,
Abstract: Trials have demonstrated that high-dose escalation followed by autologous transplantation can promote better long-term survival as salvage treatment in malignant lymphomas. The aim of the present nonrandomized clinical trial was to demonstrate the role of high-dose cyclophosphamide (HDCY) in reducing tumor burden and also to determine the effectiveness of HDCY followed by etoposide (VP-16) and methotrexate (MTX) in Hodgkin's disease plus high-dose therapy with peripheral blood progenitor cell (PBPC) transplantation as salvage treatment. From 1998 to 2000, 33 patients with a median age of 33 years (13-65) affected by aggressive non-Hodgkin's lymphoma (NHL) (60.6%) or persistent or relapsed Hodgkin's disease (39.4%) were enrolled and treated using high dose escalation (HDCY + HDVP-16 plus HDMTX in Hodgkin's disease) followed by autologous PBPC transplantation. On an "intention to treat" basis, 33 patients with malignant lymphomas were evaluated. The overall median follow-up was 400 days (40-1233). Thirty-one patients underwent autografting and received a median of 6.19 x 10(6)/kg (1.07-29.3) CD34+ cells. Patients who were chemosensitive to HDCY (N = 22) and patients who were chemoresistant (N = 11) presented an overall survival of 96 and 15%, respectively (P<0.0001). Overall survival was 92% for chemosensitive patients and 0% for patients who were still chemoresistant before transplantation (P<0.0001). Toxicity-related mortality was 12% (four patients), related to HDCY in two cases and to transplant in the other two. HDCY + HDVP-16 plus HDMTX in only Hodgkin's disease followed by autologous PBPC proved to be effective and safe as salvage treatment for chemosensitive patients affected by aggressive NHL and Hodgkin's disease, with acceptable mortality rates related to sequential treatment.
Autotransfus？o de pré-coleta imediata
Bogossian, Lev？o;Bogossian, Aníbal da Torre;
Revista do Colégio Brasileiro de Cirurgi？es , 2008, DOI: 10.1590/S0100-69912008000400009
Abstract: the practice of auto-transfusion is highly considered due to its safety and economic beneficts. it comprises two basic modalities: "reinfusion" and "pre-collection" of blood. the reinfusion uses the patient's own blood spurted either from the patient's previous hemorrhage or during the surgery. the auto-transfusion of pre-collect uses the patient's blood tajen before surgery and it consists two basic modalities: the multiple pre-collection in which the blood is taken from the patient much before the scheduled sate of the surgery and the pre-collection done 10-30 minutes before surgery, which we presently designated as "immediate pre-collection" (or pre-deposit for immediate utilization) which constitutes the basic topic of this essay.
Successful laparoscopic management of hemoperitoneum due to spontaneous venous rupture overlying a uterine fibroid  [PDF]
Kyousuke Takeuchi, Makoto Sugimoto, Taro Tsujino, Riichiro Nishino
Open Journal of Obstetrics and Gynecology (OJOG) , 2012, DOI: 10.4236/ojog.2012.22032
Abstract: Spontaneous venous rupture overlying a uterine fibroid is a rare cause of hemoperitoneum. A 38-year-old woman presented to the emergency department with acute onset of abdominal pain. The ultrasound revealed multiple fibroids and free fluid in the peritoneum. There was a significant drop of the hemoglobin and hematocrit. The patient underwent emergent exploratory laparoscopy. A subserosal uterine leiomyoma was found, with a bleeding vein on its basis and massive hemoperitoneum. Laparoscopic myomectomy was successfully performed with local injection of vasopressin and intraoperative autologous blood transfusion. This case suggests that spontaneous intraperitoneal haemorrhage associated with uterine fibroids, although rare, should be considered in women with hypovolemic shock and a pelvic mass.
Efficacy of Autologous Cultured Fibroblast Cells as a Treatment for Patients with Facial Contour Defects: A Clinical Replication Study  [PDF]
Edward Charles R. Lee, Kim Siea Lee, Jezamine Lim, Jason Yip, Cheng Zhang, Xu Zhang, Han Bin, To Lim
Journal of Cosmetics, Dermatological Sciences and Applications (JCDSA) , 2017, DOI: 10.4236/jcdsa.2017.74027
Abstract: Background: The US FDA has recently approved autologous cultured fibroblast cells (ACF) as treatment for cutaneous contour defects. ACF provides an alternative to synthetic fillers or fat grafting with the significant advantage of producing longer lasting effect. Methods: This was a prospective open label single group clinical study to demonstrate the clinical efficacy of ACF that we have replicated in our lab. The study enrolled 18 patients with nasolabial folds from 2 centres in Malaysia in 2011-2012. ACF at dose of 23 or 92 million cells were injected on 3 occasions at 4 weeks interval. Efficacy at 6- and 12-month post treatment was assessed using a standardized 7-point scale which was performed by the 2 investigators as well as a panel of 7 independent evaluators. Results: We obtained a successful outcome (primary endpoint), defined as improvement in the appearance of the nasolabial fold of at least 2 points on the 7-point scale, in 33% of patients as assessed by investigators at 12-month follow-up and in 22% of patients assessed by independent evaluators. Investigators also found 78% of patients having had a 1-point improvement from baseline while independent evaluators found 83% of patients having improved by as much. Patients were uniformly (100%) satisfied with the improvement in their appearance. No treatment-related adverse event was reported. Baseline score and follow-up duration had significant effect on treatment response. The greater the baseline severity and the longer the post-treatment follow-up, the better the response to ACF. Larger dose of cells (92 million cells) has little additional effect suggesting that the 1 mL dose (23 million cells) is near optimal. Older patients showed a trend towards poorer response but this was not statistically significant. Conclusions: We have
Single-Center Study of 83 Horses with Suspensory Injuries Treated with Adipose-Derived Stem and Regenerative Cells  [PDF]
F. Ross Rich
Stem Cell Discovery (SCD) , 2014, DOI: 10.4236/scd.2014.42005
Abstract:

Adipose-derived stem and regenerative cells (ADRCs), concentrated from autologous fat tissue, have the ability to differentiate into various specific cell types including tenocytes. In this retrospective study, clinical data are presented from 83 horses with 176 suspensory ligament injuries, treated with ADRCs, given a strictly enforced standardized rehabilitation program, and followed up for at least one year after returning to work. Assessment for a successful outcome was return to full work (RFW) at a previous or higher level of performance for one year or more without re-injury. RFW numbers were 84.6% for horses with fore-limb ligament injuries and 82.1% for horses with hind-limb injuries. RFW outcomes were slightly better in cases with proximal suspensory ligament desmitis (86.7%) compared to horses with lesions of the body and branches. The ADRC injection procedure was well tolerated; no treatment-related adverse events, including injection flares, were detected in any of the 83 horses. The demonstrated long term stability of healed lesions strongly supports the therapeutic use of regenerative cells extracted from adipose tissue for treatment of acute and chronic, fore- and hind-limb suspensory ligament injuries in horses of various athletic sport disciplines.

第1页/共1000条
每页显示 条


Home
Copyright © 2008-2020 Open Access Library. All rights reserved.